Here are the 10-K annual reports from Biote Corp. (BTMD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BTMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BTMD filings page.
biote Corp. files its 2025 annual report, reporting revenue of $192.2 million and net income of $31.6 million. Revenue was slightly below 2024’s $197.2 million, but profitability improved sharply. The company operates a hormone optimization practice-building platform and a Biote-branded dietary supplements line, serving over 9,200 practitioners in more than 5,300 clinics.
Dietary supplements contributed about 22% of 2025 revenue, and procedure-based service fees about 71%. biote highlights a large, growing hormone replacement therapy market, strong practitioner retention above 91%, and an all-cash model designed to support attractive practice economics while navigating significant regulatory oversight of supplements and compounded hormones.